Search PubMed⌕ Search

Biomedical subjects

S Makni

Publications and source records attributed to S Makni.

51 records · Page 3Linked to original sources
PubMedDate not supplied

[Antiphosphoplipid antibodies and retinal occlusive vasculopathy].

PURPOSE: to determine the prevalence of antiphospholipid antibodies in patients with occlusive retinal vascular events, exempt from conventional risk factors of retinal thrombosis. METHODS: eleven patients with retinal vascular occlusion, free of main accepted risk factors for retinal thrombosis, were retrospectively screened for antiphospholipid antibodies (anticardiolipin and anti-beta2 glycoprotein 1 antibodies) by an Elisa method. Prevalence of antiphospholipid antibodies were compared with those in a homogenous control group of 100 patients. RESULTS: the prevalence of antiphospholipid antibodies in the study group was 27% (three of 11). Comparison with control group prevalence (3%) showed a statistically significant difference (p < 0,001). One patient in the study disclosed positivity for IgG anticardiolipine antibodies, one for IgM anticardiolipine antibodies and one for anti-beta2 glycoprotein 1 antibodies. CONCLUSION: our results lead us to recommend a systematic search for specific antiphospholipid antibodies in such young patients which could have an importance for the diagnosis of primary antiphospholipid syndrome.

Adolescent↗
PubMedDate not supplied

[Prevalence of serologic markers in celiac disease in trisomy 21 in Tunisia].

PURPOSE: This study was aimed to investigate the prevalence of serologic markers of celiac disease in Tunisian patients with trisomy 21. METHODS: Twenty seven patients with trisomy 21 were prospectively screened by indirect immunofluorescence for anti-reticulin and anti-endomysium antibodies, and by an ELISA method for anti-gliadin and anti-transglutaminase antibodies. None of the 27 patients had known celiac disease at the time of the study. RESULTS: Anti-reticulin, anti-endomysium, anti-gliadin and anti-transglutaminase antibodies were found in respectively 11%, 11%, 18.5%, and 14.8% of cases. Only one patient with all serologic markers of celiac disease underwent biopsy which shows a villous atrophy. CONCLUSION: Anti-endomysium and anti-transglutaminase antibodies are good immunologic markers for the screening for celiac disease, a screening which is justified in patient with trisomy 21.

Adolescent↗
PubMedDate not supplied

[Prevalence of celiac disease serological markers in Tunisian type 1 diabetic adults].

OBJECTIVE: to evaluate the prevalence of celiac serological markers; anti-transglutaminase (ATGt), anti-endomysium (AE), anti-gliadin (AGD) and anti-reticulin (AR) antibodies; in type 1 diabetic Tunisian adults. SUBJECTS AND METHODS: 261 type 1 diabetic patients aged from 16 to 60 years were enrolled in this prospective study. IgG and IgA transglutaminase and gliadin were measured with ELISA. IgA AE were tested by indirect immunofluorescence using 2 substrates; monkey oesophagus and human umbilical cord. AR were detected by indirect immunofluorescence on rat liver, kidney and stomach. Sera IgA level was measured by turbidimetry. RESULTS: 83/261 of diabetics were positive for at least one antibody, 5.7% had ATGt-A, 3.4% AE on monkey esophagus, 3.1% AE on umbilical cordon, 18% AGD-A, 19.5% AGD-G and 3.1% AR. There was an excellent concordance between AE and ATGt (r = 0.9). Out of the 261 diabetics, 5 had an IgA deficiency and one of them has IgG AE and ATGt. CONCLUSION: serological markers of celiac disease seem to be frequent in diabetics. Nevertheless, diagnosis must be confirmed by histological studies which allow us to know the real prevalence of celiac disease in diabetic adults.

Adolescent↗
PubMedDate not supplied

[Seroimmunological profile of kala-azar in Tunisia].

165 sera of patients suffering from kala-azar were collected before and after treatment (N-methyl glucamine: Glucantime ) and analysed for anti-leishmania antibodies by the counter immunoelectrophoresis and fluorescent antibody techniques. Serum immunoglobulins G, A, M and Complement C4 and C3 were studied as well; and C reactive protein, rheumatoid factor and anti-nuclear, anti-mitochondrial and anti-smooth muscle antibodies were investigated. Before treatment, counter immuno-electrophoresis was positive in 63.88% and immunofluorescent antibody test in 94.6%. The analysis of immunoglobulins has shown an increase of IgG in nearly all cases, an increase of IgM in 78.26% of sera tested. Little change has been noted with IgA. C reactive protein has been found in 87.67% and rheumatoid factor in 76.4% of sera examined. In 4 patients, anti-smooth muscle antibodies have been found at a relatively weak dilution. A decrease of complement C4 has been observed whereas complement C3 was slightly increased. After treatment (2 cures of Glucantime ) counter immunoelectrophoresis was positive in 23.07% of cases whereas immunofluorescent antibody test was still positive in 84.62%. IgG remained increases in the whole cases and IgM in only 43,48%. C reactive protein and rheumatoid factor have been found in 14.81% and 50% of cases respectively. Complement C4 remained low whereas complement C3 showed normal mean value. The relationship between the serological disturbances observed and the prognosis were discussed.

Antibodies↗